Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2017 04/19/2017 04/20/2017 04/21/2017 04/24/2017 Date
30.92(c) 31.78(c) 31.5(c) 31.15(c) 31.52 Last
78 918 173 819 69 265 56 298 81 853 Volume
-0.55% +2.78% -0.88% -1.11% +1.19% Change
More quotes
Financials ($)
Sales 2017 360 M
EBIT 2017 0,19 M
Net income 2017 1,18 M
Finance 2017 41,9 M
Yield 2017 -
Sales 2018 396 M
EBIT 2018 13,7 M
Net income 2018 13,8 M
Finance 2018 54,8 M
Yield 2018 -
P/E ratio 2017 979,56
P/E ratio 2018 75,77
EV / Sales2017 2,83x
EV / Sales2018 2,54x
Capitalization 1 061 M
More Financials
Company
Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.Its uses a platform which translates a massive... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
04/06 GENOMIC HEALTH : Oncotype DX Predicts 10-year Risk of Developing Metastatic Pro..
03/30 GENOMIC HEALTH : Multiple Presentations at 15th St. Gallen International Breast ..
03/30 GENOMIC HEALTH : Published Outcomes Results from SEER Registries Indicates That ..
03/30 GENOMIC HEALTH : New Research Shows Oncotype DX Breast Cancer Test Helps Reduce..
03/29 GENOMIC HEALTH : Oncotype DX Predicts 10-year Risk of Developing Metastatic Pro..
03/24 GENOMIC HEALTH : Published Outcomes Results from SEER Registries Indicates That ..
03/15 GENOMIC HEALTH : Management's Discussion and Analysis of Financial Condition and..
02/28 GENOMIC HEALTH : to Present at the Cowen and Company 37th Annual Health Care Con..
02/16 GENOMIC HEALTH : Four New Studies of Oncotype DX Genomic Prostate Score™ ..
02/16 GENOMIC HEALTH : Four New Studies of Oncotype DX Genomic Prostate Score(TM) (GP..
More news
Sector news : Biotechnology & Medical Research - NEC
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/19Highbridge Capital Management LLC Invests $274,000 in Genomic Health, Inc. $G.. 
04/18Genomic Health, Inc. $GHDX Cut to Strong Sell at Zacks Investment Research  
04/18Genomic Health downgraded by Zacks Investment Research to strong sell.  
04/18First National Bank of Omaha Purchases 4,553 Shares of Genomic Health, Inc. $.. 
04/13-$0.05 Earnings Per Share Expected for Genomic Health, Inc. $GHDX This Quarte.. 
More tweets
Qtime:15
News from SeekingAlpha
04/06 FDA OKs direct-to-consumer genetic tests
02/14 Genomic Health's (GHDX) CEO Kim Popovits on Q4 2016 Results - Earnings Call T..
02/14 Genomic Health beats by $0.05, misses on revenue
02/13 Notable earnings after Tuesday?s close
01/18 Premarket analyst action - healthcare
Advertisement
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Full-screen chart
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 31,8 $
Spread / Average Target 1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole COO, CFO & Principal Accounting Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Michael Vedda Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.5.99%1 061
INCYTE CORPORATION22.68%25 166
QUINTILES IMS HOLDINGS..8.15%19 405
LONZA GROUP AG8.28%11 101
CELLTRION, INC.--.--%9 762
SEATTLE GENETICS, INC.23.82%9 319
More Results